Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,516,500
  • Shares Outstanding, K 211,480
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.72
  • Price/Sales 5.71
  • Price/Cash Flow 13.07
  • Price/Book 5.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
305.00 +1.30%
on 10/27/17
320.25 -3.52%
on 10/25/17
-6.76 (-2.14%)
since 10/24/17
3-Month
284.89 +8.45%
on 08/25/17
348.84 -11.43%
on 10/18/17
+23.52 (+8.24%)
since 08/24/17
52-Week
244.28 +26.48%
on 05/31/17
348.84 -11.43%
on 10/18/17
+27.17 (+9.64%)
since 11/23/16

Most Recent Stories

More News
Should You Buy the Beaten Down Blue-Chip Stocks?

Just because a stock plunges to multi-year lows, that doesn't mean it's a value stock.

XOM : 81.42 (+0.39%)
CMG : 279.31 (-0.70%)
M : 21.07 (+2.13%)
GE : 18.19 (+0.22%)
BIIB : 308.97 (-0.27%)
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

CELG : 104.50 (-0.63%)
CYTK : 7.60 (-4.70%)
RARE : 48.91 (-0.06%)
ACOR : 20.50 (+1.23%)
TSRO : 83.41 (-0.60%)
UTHR : 125.01 (-0.32%)
BIIB : 308.97 (-0.27%)
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer

Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December 11, 2017.

BIIB : 308.97 (-0.27%)
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference. The webcast will be live on Wednesday, November 29, 2017...

BIIB : 308.97 (-0.27%)
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3

After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.

CELG : 104.50 (-0.63%)
VRTX : 146.55 (-0.33%)
ABBV : 94.72 (+0.26%)
GILD : 72.46 (-0.49%)
AMGN : 170.12 (+0.09%)
ALXN : 108.61 (+0.94%)
BIIB : 308.97 (-0.27%)
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease

Eisai Co., Ltd. announced today that Biogen Inc. (Nasdaq: BIIB) presented new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, an investigational treatment for Alzheimer's...

ESALF : 55.1500 (-0.18%)
BIIB : 308.97 (-0.27%)
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

LGND : 133.71 (+0.49%)
PDLI : 2.88 (+0.35%)
VRX : 16.57 (+0.18%)
BIIB : 308.97 (-0.27%)
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation

Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation.

BIIB : 308.97 (-0.27%)
Earnings Review and Free Research Report: Biogen's Adjusted EPS Surged 25.1%

Research Desk Line-up: Seattle Genetics Post Earnings Coverage

SGEN : 58.94 (-0.32%)
BIIB : 308.97 (-0.27%)
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab

--The results at two years in the titration regimen group were consistent with the dose- and time-dependent results observed in the treatment groups that received a fixed-dose of 3, 6 or 10 mg/kg aducanumab...

BIIB : 308.97 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 311.94
1st Resistance Point 310.46
Last Price 308.97
1st Support Level 307.38
2nd Support Level 305.78

See More

52-Week High 348.84
Last Price 308.97
Fibonacci 61.8% 308.90
Fibonacci 50% 296.56
Fibonacci 38.2% 284.22
52-Week Low 244.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart